Erlotinib in cancer treatment
MA Bareschino, C Schettino, T Troiani, E Martinelli… - Annals of oncology, 2007 - Elsevier
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …
Review of erlotinib in the treatment of advanced non-small cell lung cancer
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …
Erlotinib: a new therapeutic approach for non-small cell lung cancer
P Bonomi - Expert opinion on investigational drugs, 2003 - Taylor & Francis
Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
C Schettino, MA Bareschino, V Ricci… - Expert review of …, 2008 - Taylor & Francis
Approximately 213,380 new cases of non-small-cell lung cancer (NSCLC) were estimated to
occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of …
occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of …
A review of erlotinib–an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
R Iyer, A Bharthuar - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
Erlotinib in the treatment of advanced pancreatic cancer
RK Kelley, AH Ko - Biologics: Targets and Therapy, 2008 - Taylor & Francis
Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
over the past decade. Multiple trials of newer chemotherapeutic agents both alone and in …
Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer
J Smith - Clinical therapeutics, 2005 - Elsevier
BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
Erlotinib hydrochloride.
JD Minna, J Dowell - Nature Reviews. Drug Discovery, 2005 - europepmc.org
Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a
class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor …
class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor …
Erlotinib hydrochloride.
J Dowell, JD Minna, P Kirkpatrick - Nature Reviews Drug Discovery, 2005 - nature.com
Abstract Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
T Dragovich, M Huberman, DD Von Hoff… - Cancer chemotherapy …, 2007 - Springer
Purpose The purpose of this phase IB trial was to evaluate the tolerability, pharmacokinetics
and preliminary evidence of antitumor activity of erlotinib plus gemcitabine in patients with …
and preliminary evidence of antitumor activity of erlotinib plus gemcitabine in patients with …